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Abstract
The most recent World Health Organization report revealed that the number of adults 
suffering from diabetes has almost quadrupled since 1980 to 422 million, thus drawing 
attention to the urgent need to step up prevention and treatment of this disease. This 
chronic ailment is often associated with serious complications such as increased risk of 
heart disease, stroke and kidney failure. In 2012 alone, diabetes lead to 1.5 million deaths. 
This dramatic rise is mainly due to the increased prevalence of type 2 diabetes and fac-
tors driving it include overweight and obesity. Novel studies in this area have advanced 
our understanding regarding the complex relationship between diet, gut microbiota 
and diabetes. Despite no clear microbiota signature is associated with diabetes, patients 
harbour a reduction of butyrate-producing species (Faecalibacterium prausnitzii, Roseburia 
intestinalis) as well as an increase in opportunistic pathogens. Furthermore, the func-
tions of the gut microbiome (i.e., vitamin metabolism, transport of sugars, carbohydrate 
metabolism, short chain fatty acid (SCFA) synthesis, etc.) are also different in patients 
with type 2 diabetes, a fact that may significantly alter the course of disease. Diet is 
one of the most decisive factors that have an impact on the gut microbiome. Nutritional 
interventions using prebiotics (i.e., inulin-type fructans), polyphenols and arabinox-
ylans have been employed for the treatment of diabetes. Besides the shifts produced by 
these dietary components in the microbiome composition, it is worth mentioning their 
impact on host physiology through modulation of gut peptide production and glucose 
metabolism. The information presented within this chapter summarizes the most recent 
advances in the study of the microbiome-diet-diabetes interplay and analyses how these 
novel findings can be used in order to establish new therapeutic approaches for those 
with diabetes.
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1. Diabetes: the “silent killer”
Diabetes mellitus (DM) is defined as “a heterogeneous syndrome characterized by a complex 
disorder in regulating the body’s energy metabolism, which also affects the use of carbo-
hydrates, lipids and proteins” [1]. Several processes are involved in the evolution of diabe-
tes pathology ranging from autoimmune pancreatic β cells destruction that induces insulin 
deficiency, up to anomalies, which causes insulin resistance. Increased blood glucose levels 
(≥126 mg/dL), blood glucose at 2 h after 75 g oral glucose (≥200 mg/dL), HbA1c (≥6.5%), or all 
of them characterize diabetes mellitus simultaneously. The American Diabetes Association 
(ADA) has classified diabetes mellitus into several types: (i) type 1 DM (T1D)—character-
ized by the destruction of pancreatic β cells; (ii) type 2 DM (T2D)—characterized by a pro-
gressive deficiency of insulin secretion on a background of pre-existing insulin resistance; 
(iii) gestational DM—diabetes diagnosed during pregnancy; and (iv) other specific types of 
diabetes due to other causes such as genetic defects of β pancreatic cells, genetic defects in the 
action of insulin, diseases of exocrine pancreas, endocrinopathies, diabetes induced by drugs 
or chemicals, etc. Type 1 diabetes (T1D) also known as juvenile diabetes or insulin-depen-
dent diabetes mellitus is a very common autoimmune disorder in children and adolescents, 
and it is caused by the cellular-mediated autoimmune destruction of pancreatic β-cells, lead-
ing to an absolute insulin deficiency, which interferes with glucose metabolism [2]. T1D has 
two variants: (i) type I A is due to the destruction of the pancreatic cells under the influence 
of immune factors, in which case autoantibodies to islet cells can be detected in serum and 
(ii) type I B in which the pancreatic β-cell lysis occurs in the absence of an obvious anti-pan-
creatic mechanism [3]. Patients with this type of diabetes are usually young (under 30 years), 
have normal weight and require continuous insulin administration for survival. T1D symp-
toms are usually present with the onset of hyperglycaemia and include polyphagia, poly-
dipsia, polyuria, weight loss, paraesthesia, recurrent infections and ketoacidosis tendency. 
The T1D prevalence of 1:300 is increasing worldwide, and it represents 5–10% of all diabetes 
mellitus cases [4]. The main cause of T1D is genetic predisposition with the human leucocyte 
antigen (HLA) DR3-DQ2 and DR4-DQ8 haplotypes as the most prevalent variants involved, 
which are common for other autoimmune diseases such as celiac disease [5]. Besides genetic 
predisposition, other factors such as infections, birth delivery mode, diet and the use of anti-
biotics have all been linked to T1D development [6], but the mechanisms linking them to T1D 
development are not clear.
DM type 2 (T2D) comprises a heterogeneous group of conditions characterized by varying 
degrees of insulin resistance or inappropriate insulin secretion and elevated plasma glucose 
(hyperglycaemia). Hyperglycaemia of this type of diabetes is due to genetic or metabolic 
defects of insulin synthesis and/or secretion, which once identified have become particularly 
important in discovering new effective therapeutic means. Pre-diabetes stages (IFG and IGT) 
typically precede T2D [7]. T2D appears at the age of 40 or above and is not associated with 
autoimmune aetiology but with metabolic syndrome involving hypertension, atherosclerotic 
cardiovascular disease, low high density lipoprotein cholesterol (HDLc), high circulating 
level of low density lipoprotein cholesterol (LDLc), decreased fibrinolysis, increased plasma 
lipopolysaccharide (LPS) due to alteration of mucosal permeability, obesity and especially 
Pathophysiology - Altered Physiological States70
visceral or abdominal type of obesity (visceral fat tissue is more metabolically active than the 
subcutaneous adipose tissue), producing pro-inflammatory adipokines and peripheral insu-
lin resistance. According to the ADA guidelines of 2016: “Standards of medical care in diabe-
tes” (Diabetes Care), the criteria for the diagnosis of T2D refer to: (i) Glucose concentration in 
venous blood (fasting plasma glucose) ≥126 mg/dL (7.0 mmol/L) in at least two consecutive 
determinations, measured after at least 8 h of fasting; (ii) Glucose concentration in venous 
blood 2 h after oral glucose tolerance test—OGTT—(ingestion of 75 g of anhydrous glucose 
dissolved in water) ≥200 mg/dL (11.1 mmol/L); (iii) HbA1C ≥48 mmol/mol determined in the 
medical laboratory by the National Glycohemoglobin Standardization Program (NGSP) and 
standardized by DCCT (Diabetes Control and Complications Trial); and (iv) Glucose con-
centration in venous blood ≥200 mg/dL (11.1 mmol/L) randomly determined in hyperglycae-
mic individuals. Some potential risk factors for T2D are family history and race. Specifically, 
Hispanic, Asian American, or Indian Americans are at greater risk to develop T2D. Age is 
another risk factor worth considering, as individuals who are 40–45 years old or older have 
a greater risk for developing the condition. Diabetic patients have an increased incidence 
of cardiovascular disease, atherosclerosis, peripheral arteriopathy and cerebrovascular dis-
ease. Long-term complications of diabetes include retinopathy with possible loss of vision, 
nephropathy followed in time by renal insufficiency, peripheral neuropathy with risk of leg 
ulceration and amputation. Neuropathy autonomously induces gastrointestinal, genitouri-
nary, cardiovascular and sexual dysfunction. Like most other conditions, the earlier that dia-
betes is detected, the more successfully it can be managed. There is no cure for type 2 diabetes, 
but it can be very well managed if identified early. The latest data released by a group of 
WHO experts provide an alarming prognosis of the diabetes epidemic. It is estimated that by 
2025, there will be 324 million people with diabetes. Thus, the prevalence will increase from 
2.8% (2000) to 4.3% (2025). The T2D epidemic is considered one of the worst in the history 
of humankind. What is alarming, however, is that at the time of T2D diagnosis, a large per-
centage of people already have chronic complications and/or morbid associations. The WHO 
predictions for 2030 place T2D as the seventh cause of death worldwide. Epidemiological 
data revealed an increased prevalence for both obesity and T2D in developed countries, sug-
gesting the role of diet and lifestyle in the pathogenesis of these two diseases [1]. Recently, 
it has been shown that overeating saturated fats and refined sugars can lead to dyslipidemia 
and insulin resistance. Thus, T2D prevalence is directly proportional to the energy intake of 
saturated fatty acids [8]. Currently, type 2 diabetes is most commonly encountered in most 
cases associated with overweight or obesity in adults. WHO classifies obesity grades by 
the formula: Body Mass Index (BMI) = weight/height2 in: (i) Overweight—BMI 25–29.9 kg/
m2; (ii) Grade I obesity—BMI 30–34.9 kg/m2; (iii) Grade II obesity—BMI 35–39.9 kg/m2; and 
(iv) Grade III obesity—BMI > 40 kg/m2. In T2D, the most common type of obesity is the cen-
tral or abdominal type [9]. An increased prevalence of T2D in the predominantly abdominal 
distribution of adipose tissue was reported independent of the degree of obesity [10]. On the 
other hand, there are studies that show that obesity is not sufficient or mandatory for the 
appearance of T2D. In support of this hypothesis, there are several arguments: the presence 
of T2D in a normal weight phenotype, the existence of populations with high prevalence of 
obesity, but the low prevalence of T2D, the predominance of obesity in females, in contrast to 
that of T2D that does not differ between genders and finally data according to which in most 
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populations studied most obese individuals do not have T2D [1]. Cross-sectional studies have 
failed to determine a causal relationship between T2D and obesity or a common factor trig-
gering both diseases, but prospective and longitudinal studies have provided some evidence 
of the direct role of obesity in T2D pathogenesis. Prospective studies on the populations of 
Japan, Sweden and the Pima Indians show that the central distribution of body adiposity is a 
major risk factor for the emergence of T2D, regardless of the degree of obesity [11]. However, 
these studies only suggest that insulin synthesis or deficiency obesity and defects predispose 
to T2D but offer little data on the duration of these anomalies or their interaction [1]. There is 
increasing evidence that adipose tissue has a limited capacity to store the energy surplus [12] 
and that overstressed adipocytes suffer a process of apoptosis or necrosis, precipitating an 
inflammatory response which contribute to the development of insulin resistance [13].
The specificity of obesity in T2D is also the infiltration of adipose tissue with monocytes and acti-
vated macrophages leading to the synthesis of pro-inflammatory cytokines (IL-6 and TNF-α). 
Because of changes induced in the adipose tissue (lipolysis and lipids products), hepatic lipid 
synthesis (especially of very low-density lipoproteins-VLDL and triglycerides) occurs. Due to 
the changes in lipid metabolism, T2D is also characterized by dyslipidemia (elevated triglyc-
erides, LDL-C levels and low HDLc) [14].
2. The gut microbiota-evolution, composition and functions
The gut microbiota is a dynamic system composed of tens of trillions of microorganisms, 
which carry out essential functions for the human host. The first composition of the micro-
biota is acquired at birth when microorganisms from the mother and the environment rap-
idly colonize the neonatal gastrointestinal tract. Thus, the delivery mode is a keystone factor 
which determines whether the newborn is colonized by Lactobacillus, Prevotella or Sneathia 
spp. from the birth canal or by Staphylococcus sp. and Propionibacterium spp. coming from the 
skin of the mother and other participants in the caesarean section [15].
Subsequently birth, diet becomes the main modulator of the microbiota composition. In line 
with this, breastfeeding babies harbour a distinct microbiota from formula-fed babies. While 
breastfeeding enhances the prevalence of lactic acid bacteria, infant formulas promote the 
enrichments of species like Staphylococcus aureus and Bacteroides spp. Until 3 years of age, the 
microbiota is highly influenced by diet and disease and, in time, its composition becomes very 
similar to one of the adults [16]. At around 7 years old, 90% of the microbiota is composed 
of bacteria from the phyla Bacteroidetes and Firmicutes, while the remaining 10% is made of 
Proteobacteria, Tenericutes and Cyanobacteria [17]. A study by Arumugam et al. proposed the 
existence of three gut enterotypes for the entire world population: Bacteroides, Rumincoccus and 
Prevotella [18]. Furthermore, these enterotypes were linked to dietary patterns [19]. For instance, 
the Prevotella enterotype was found to be more prevalent in case of individuals that had a diet 
rich in fibre and low in fat, whereas the Bacteroides enterotype was characteristic for people 
eating a diet dominated by animal fat and protein. In addition, recent studies have investi-
gated school-age children from different regions of the world and highlighted the role of age, 
diet, geographical localization and traditions in shaping the microbiota. Children from Mexico, 
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Indonesia, Thailand and Malawi have a diet with a low level of animal protein and fat and a high 
content of plant polysaccharides and fibre, which translate into a microbiota rich in Prevotella. 
Conversely, children from Japan, the United States, Italy and China have a Western diet rich in 
fat, animal protein and low in fibre and thus have a microbiota dominated by Bacteroides [17]. 
However, the enterotype hypothesis was recently challenged by Knights et al. who showed that 
enterotypes can vary widely and continuously over time within an individual [20].
The gastrointestinal (GI) tract of a healthy host is home to 102 microbial cells within the stomach 
into the duodenum and jejunum, whereas the distal ileum harbours around 108 microbial cells. 
However, the highest microbial level (around 1012 cells) resides in the highly anaerobic environ-
ment of the colon. Since most of these microbes are not cultivatable, the advent of culture-inde-
pendent sequencing has provided a valuable insight into the composition of the microbiota in 
health and disease conditions. Despite the large volume of data generated by sequencing technol-
ogies, our understanding of the functional properties of these microorganisms comes from germ-
free animals. Thus, animals, which were born and reared under sterile conditions, have provided 
strong evidence regarding the role of microbiota in shaping immunity, host metabolism and even 
social development. Unlike animals reared under specific pathogen-free (SPF) conditions, germ-
free animals were shown to have a defective development of the immune system with impaired 
development of the gut-associated lymphoid tissue, with fewer and smaller Peyer’s patches [21].
3. The immunity-diet-microbiota interplay in type 1 diabetes
The microbiota modulates the immune response of the host even before birth as suggested 
by the fact that the intrauterine environment is not completely sterile. Indeed, there is evi-
dence that the placenta harbours a low-abundance commensal microbiota similar to the oral 
microbiota [22]. Thus, the foetus is exposed to antigens against which it has to develop immu-
nological tolerance. Following birth, diet represents the crucial factor guiding microbiota 
composition as well as immunity. Dietary antigens correlated with T1D are modulated by 
feeding regimens (breast milk vs infant formula) and the introduction of solid foods (particu-
larly of wheat). While infant formula has been historically associated with T1D, breast milk 
has beneficial immunomodulatory effects in the neonatal gut. Within this line of thought, 
studies in mice showed that sIgA transferred passively in breast milk promotes gut homeo-
stasis and prevents bacterial translocation [23].
Studies in Finnish and American children revealed that fat and protein intake from milk 
products promote a risk of advanced β-cell autoimmunity and consequently progression to 
T1D [24]. Patients with T1D and latent autoimmune diabetes of adults were shown to have 
elevated titres of anti-β-casein antibodies. Several bovine β-casein variants have a Pro-Gly-
Pro-Ile-Pro motif in their sequence, which is also present in the glucose transporter GLUT2. 
Hence, a plausible explanation for pancreatic damage is a cross reactivity of the immune 
system initially targeted against the dietary antigen in milk.
T1D is similar in terms of its genetic HLA-associated risk with celiac disease and T1D children 
have an altered T-cell reactivity against wheat antigens in the gut [25]. Consequently, diets 
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high in gluten are considered an important culprit for microbiota changes and T1D develop-
ment [26]. Thus, introduction of gluten-containing foods between 3 and 7 months of age can 
significantly decrease the risk of T1D autoimmunity [27].
Gluten is a well-known trigger for celiac disease and recently for T1D due to its effects on gut 
permeability. As a consequence of the impaired gut barrier, gliadin peptides move across the 
epithelium into the lamina propria where they are detected by dendritic cells. Dendritic cells 
recognize gliadin peptides and migrate to other sites including the pancreatic lymph nodes 
where they activate autoreactive T cells [27].
4. The microbiota in type 1 diabetes
The involvement of the intestinal microbiota in the pathophysiology of T1D was highlighted 
by several animal studies. Valuable insights into the role of microbiota in diabetes pathogen-
esis were obtained using diabetes prone animals, specifically non-obese diabetic (NOD) mice 
and bio-breeding diabetes prone (BB-DP) rats.
Initial studies showed that NOD mice with chronic viral infection were characterized by a 
lower diabetes incidence [28]. Mycobacteria infection and stimulation with bacterial antigens 
lowered the incidence of diabetes development in NOD mice suggesting that a germ-free 
niche augments the risk of diabetes development [29]. However, this is not the case since 
recent studies suggested that rather certain microbes (i.e., Bacillus cereus) were modulating the 
risk of diabetes development [30].
Within a study by Brugman et al., the use of BB-DP rats and fluorescence in situ hybridization 
targeted against the 16S rRNA of Clostridium, Lactobacillus and Bacteroides showed that rats 
that developed diabetes harboured higher levels of Bacteroides [31]. Further investigations 
revealed that BB-DP rats had a microbiota with lower levels of Lactobacillus and Bifidobacterium 
when compared to diabetes-free rats. More recently, Patterson et al. used the streptozocin 
(STZ)-induced T1D rat model to offer information regarding diabetes onset and progression 
in terms of microbial shifts [32].Thus, T1D was linked to a shift in the Bacteroidetes:Firmicutes 
ratio, whereas later T1D progression was characterized by an enrichment of lactic acid bacte-
ria (i.e., Lactobacillus, Bifidobacterium). In addition, STZ-induced T1D rats exhibited a reduced 
microbial diversity 1 week after disease onset, and this diminished diversity was maintained 
throughout the study.
Importantly, the integrity of the intestinal epithelium plays a pivotal role in the functioning of 
the immune system by regulating the passage of antigens to dendritic cells. A compromised 
barrier epithelium is associated with increased gut permeability, which favours the exposure 
to antigens and may subsequently lead to autoimmunity. T1D prone rats were shown to have 
increased gut permeability and diminished levels of the tight junction protein claudin [33]. 
Furthermore, upregulation of the protein zonulin which regulates tight junctions increased 
intestinal permeability and the prevalence of diabetes in BB-DP rats [34]. Within this line of 
thought, a study using the BB-DP rat model hypothesized that administration of Lactobacillus 
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johnsonii N6.2 delayed diabetes development via regulation of gut integrity, specifically by 
increasing the tight junction protein claudin-1 [35].
MyD88 is an adapter protein downstream of multiple toll-like receptors involved in sensing of 
microorganisms. The knock out of this protein in the NOD mouse was shown to protect against 
diabetes. Importantly, heterozygous MyD88KO/+ NOD mice, which normally develop dis-
ease, are protected from diabetes when colonized from birth with the intestinal microbiota of a 
MyD88-KO NOD donor mouse [36]. Thus, disease progression in the NOD mouse is partially 
determined by an exacerbated innate immune response to commensal microbiota, and changes 
in the composition of the microbiota may diminish this response and counteract disease.
Considerable effort has been made in the last years in order to provide more information 
regarding the composition of the diabetogenic microbiota in humans. As expected, the pat-
tern of bacterial abundance is distinct between different studies due to variations caused by 
ethnicity, geography and age. Despite these variations, all studies have shown Bacteroides 
as a main driver for T1D-associated dysbiosis. Indeed, there is a direct relation between the 
abundance of Bacteroides and T1D-associated autoantibodies [37, 38]. However, another study 
found no difference in Bacteroides levels when analysing children with anti-islet cell autoim-
munity versus healthy controls [39].
Dysbiosis was linked to autoimmunity and subsequent progression to T1D. Importantly, the 
appearance of β-cell autoimmunity precedes the onset of hyperglycemia for over 15 years 
[40]. Therefore, targeting the microbiota could potentially postpone T1D development in chil-
dren with β-cell autoimmunity.
Recently, Kostic et al. highlighted specific features of the T1D microbiome [38]. The study 
investigated 33 infants from Finland and Estonia who were genetically predisposed to dia-
betes and observed a relative 25% reduction in alpha-diversity in T1D patients compared 
to non-converters and seroconverters (positive for at least two of the autoantibodies anal-
ysed including insulin autoantibodies, islet cell antibodies, islet antigen-2 antibodies and glu-
tamic acid carboxylase antibodies). Microbiota shifts were evident in T1D children but not in 
the seroconverters without disease. T1D subjects were shown to harbour an enrichment of 
“pathobionts that is of commensal bacteria able to become pathogens such as Rikenellaceae, 
Blautia and the Ruminococcus and Streptococcus genera.” Furthermore, the authors observed a 
depletion of bacteria such as Lachnospiraceae and Veillonellaceae, which are commonly under 
abundant in inflammatory conditions (Figure 1).
A healthy gut microbiota is enriched with butyrate producers (i.e., Faecalibacterium) which 
determine elevated production of mucin and increased tight junction assembly which all 
determine an elevated epithelial integrity (Figure 1). A niche with high mucin production 
favours the enrichment of mucin degrading bacteria such as Akkermansia muciniphila. T1D 
subjects were reported to be colonized by lower levels of butyrate producing microorganisms 
such as Roseburia and Faecalibacterium and of mucin degrading bacteria such as Akkermansia 
and Prevotella [37, 41, 42]. In addition, the Bacteroidete: Firmicutes ratio was proposed as an 
early marker for autoimmune diseases since a higher level of Bacteroidetes was evident in 
children who developed T1D [43].
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5. Diet and type 2 diabetes
Food intake has been strongly associated to diabetes and obesity not only in terms of 
quantity but also in terms of quality of diet. The food shortage and famine during the 
two World Wars has significantly decreased the diabetes mortality in countries around 
Europe. However, in countries like the United States of America and Japan, where there 
was no shortage of food, there was no change in diabetes mortality [44]. Almost two 
decades ago, the role of diet in T2D was suggested by the observation that diabetes was 
prevalent among rich people who had an easier access to food such as refined sugar, 
flour and oil [45]. While in the past it was considered a disease of the rich, nowadays T2D 
is more prevalent among those with a lower income. Many studies have shown a strong 
correlation between high intake of sugars and development of T2D. A study by Ludwig 
et al. analysed 500 ethnically diverse children for a period of 19 months and reported that 
the frequency of obesity increased for each additional serving of carbonated soft drinks 
consumed [46]. Several prospective studies revealed link between fat intake and subse-
quent risk of developing T2DM. A diabetes study involving more than a thousand sub-
jects without a prior diagnosis of diabetes which were investigated for a period of 4 years 
reported a relationship among T2D, impaired glucose tolerance and fat intake [47, 48]. 
The high levels of fructose corn syrup used for the manufacturing soft drinks increase 
the blood glucose levels and the body mass index, thus suggesting that the intake of soft 
Figure 1. The microbiota in type 1 diabetes. Individuals with type 1 diabetes have an impaired gut barrier function 
with a thinner mucus layer and increased intestinal permeability. Their microbiota is enriched in Bacteroides, Blautia, 
Streptococcus and Rikenellaceae but low in butyrate producers such as Faecalibacterium prausnitzii and mucin degraders 
such as Akkermansia muciniphila.
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drinks is linked with obesity and T2D [49]. In addition, diet soft drinks were reported to 
contain glycated chemicals, which significantly enhance insulin resistance [50]. Whereas 
high consumption of sweets, red meat and fried foods lead to an increased risk of insu-
lin resistance and T2DM [51], a diet rich in fruits and vegetables may prevent disease 
development [52]. In addition, interventional studies revealed that high carbohydrate 
and high monounsaturated fat diets improved insulin sensitivity [53], whereas increased 
intake of white rice leads to an increased risk of T2D in Japanese women [54].
6. Popular diets and their impact on the microbiota
The most popular diets include omnivore, vegetarian, gluten-free, vegan, Western and 
Mediterranean. All of these dietary regimes have been studied regarding their role in shap-
ing the microbiota. A gluten-free diet was associated with a decrease in Bifidobacterium and 
Lactobacillus, while populations of pathobionts (potentially unhealthy microbes), such as 
Escherichia coli and total Enterobacteriaceae, increased in parallel to reductions in polysaccha-
ride intake after beginning the diet [55]. In another study by Bonder et al., a short-term gluten-
free diet lead to reductions in Ruminococcus bromii and Roseburia faecis and an increase in 
Victivallaceae and Clostridiaceae [56].
The Western diet which is low in fibre but high in animal protein and fat was associated with 
a decrease in the total bacterial load and with lower levels of beneficial commensals such as 
Bifidobacterium and Eubacterium sp. [19, 57]. Importantly, consumption of a Western diet has 
also been linked with the generation of cancer-promoting nitrosamines [58]. Both vegan and 
vegetarian diets are high in fermentable plant-based foods. When comparing a vegan or a 
vegetarian diet to an omnivorous diet, it was reported that vegan and vegetarian individuals 
had lower abundance of Bacteroides and Bifidobacterium species [59].
The traditional Mediterranean diet consists of vegetables, olive oil, cereals, legumes, nuts, moder-
ate consumption of poultry, fish and wine and a low consumption of dairy products, red meat 
and refined sugars [60]. Among the different diets, the Mediterranean diet is regarded as a healthy 
balanced diet due to its beneficial content of monounsaturated and polyunsaturated fatty acids, 
elevated vegetable protein content and high levels of antioxidants and fibre. The Mediterranean 
diet was associated with a high abundance of Lactobacillus, Bifidobacterium and Prevotella, and 
a decrease in Clostridium [61]. Furthermore, those consuming a Mediterranean diet exhibited 
increased levels of short chain fatty acids (SCFAs) and low urinary trim ethylamine oxide, which 
is associated with elevated cardiovascular risk [62]. The effects mediated by the Mediterranean 
diet include weight loss, improvement of the lipid profile and the decrease of inflammation.
7. Diet-microbiota interactions shape the risk of type 2 diabetes
Diet represents the main modulator of the composition and metabolism of the gut micro-
biota. The main macronutrients represented by proteins, carbohydrates and fats have a 
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crucial impact on the microbiome. The role of dietary protein in shaping the microbiota 
has been described since 1977 when individuals who consumed a diet rich in beef har-
boured elevated levels of Bacteroides and Clostridia and low levels of Bifidobacterium ado-
lescentis compared to those who had a meatless diet [63]. Several studies have recently 
used different forms of protein  including vegetarian pea protein, whey protein and ani-
mal protein (meats, eggs and cheese) and correlated protein consumption with microbial 
diversity [61]. Conversely, the consumption of animal-based protein positively correlated 
with the abundance of bile-tolerant anaerobes such as Alistipes, Bacteroides and Bilophila 
[64]. Even though it may promote a greater weight loss, a protein-rich diet can also be 
detrimental. Thus, individuals on a high protein/low carbohydrate diet had a microbiota 
with diminished levels of Roseburia and Eubacterium rectale and low levels of butyrate in 
their feces [65]. Similarly, patients with inflammatory bowel disease (IBD) had a similar 
microbiota signature, with low levels of Roseburia and decreased butyrate levels [66]. In 
addition, elevated intake of red meat has been linked to elevated levels of the proathero-
genic trimethylamine-N-oxide (TMAO) [62]. Animal studies have shown that high protein 
consumption increases the levels of insulin-like growth factor 1 (IGF-1), which are known 
to be correlated with a high risk of diabetes and overall mortality. Indeed, proteins of veg-
etarian origin have been linked to a lower mortality in comparison with animal-derived 
proteins [67].
In addition to high protein content, animal-based diets are also high in fat. The well-known 
Western diet, which is nowadays the main culprit for obesity and diabetes development, is 
high in saturated and trans fats and low in mono and polyunsaturated fats [61]. While con-
sumption of high saturated and trans fat diets increases cholesterol levels and is associated 
with a risk of cardiovascular disease, mono and polyunsaturated fats decrease the risk of 
chronic disease [68]. Human studies have revealed that a high-fat diet increases the abun-
dance of total anaerobic microorganisms and the levels of Bacteroides as well [19, 57]. The 
consumption of different types of fat has different effects on the microbiome. Consumption 
of a low fat diet promotes the overabundance of Bifidobacterium and leads to a reduction 
of fasting glucose and total cholesterol. Conversely, a high saturated fat diet determined 
the establishment of a microbiota enriched in Faecalibacterium prausnitzii, and a diet high in 
monounsaturated fat was correlated to a reduced total bacterial load and reduced choles-
terol [69].
Animal studies revealed that a high fat diet promotes a microbiota with less Lactobacillus 
intestinalis and with more Clostridiales, Bacteroides and Enterobacteriales. In addition, the 
abundance of L. intestinalis was negatively correlated with fat mass and body weight [70]. 
Studies in mice compared the effects of different type of lipids on the microbiota. Thus, 
lard-fed mice harboured elevated Bacteroides and Bilophila whereas mice fed with fish oil 
had increased lactic acid bacteria (Lactobacillus and Streptococcus), increased Verrucomicrobia 
(A. muciniphila) and Actinobacteria (Bifidobacterium and Adlercreutzia). In addition, lard-fed 
mice had white adipose tissue inflammation and impaired insulin sensitivity compared to 
fish oil-fed mice [71].
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Among all the dietary macronutrients, carbohydrates are the most studied. Based on 
their ability to be degraded enzymatically in the small intestine, carbohydrates are either 
digestible (i.e., starch and sugars including glucose, lactose, fructose and sucrose) or non-
digestible (resistant starch and fibre). Upon degradation, digestible carbohydrates release 
glucose into the bloodstream and lead to an insulin response [61]. Humans who were fed 
high levels of glucose, fructose and sucrose in the form of dates had a microbiota enriched 
in Bifidobacteria, and low in Bacteroides [72, 73]. Moreover, the addition of lactose to the 
aforementioned diet replicated the same bacterial shifts but it also decreased the levels of 
Clostridia species [74].
Recently, a subject of debate in the field of carbohydrates and their role in shaping the micro-
biota is represented by the use of artificial sweeteners. Artificial sweeteners such as saccharin, 
sucralose and aspartame were intended to be a healthier, no-calorie food additive for replacing 
natural sugar. However, recent work by Suez et al. showed that artificial sweeteners are more 
prone to induce glucose intolerance than consumption of sucrose or glucose. The effects exhib-
ited by artificial sweeteners were attributed to the induction of microbiota changes character-
ized by increased abundance of Bacteroides and decreased Lactobacillus reuteri [75]. Conversely, 
the use of natural sugars such as fructose, sucrose and glucose promoted microbiota shifts 
exactly opposed the ones induced by the use of artificial sweeteners.
Unlike digestible carbohydrates, non-indigestible carbohydrates are not digested in the 
small bowel but rather reach the colon where they undergo fermentation by commensal 
microbiota leading to SCFAs production such as butyrate, propionate and acetate. Butyrate 
is an important energy source for intestinal epithelial cells and a modulator of enterocyte 
differentiation, proliferation and restitution. Loss of microbial producers of SCFA can alter 
the communication between host epithelium and resident bacteria, thus contributing to the 
development of colitis. For instance, F. prausnitz ii is depleted not only in IBD patients [66] 
but also in diabetics.
Dietary fibres are essential for intestinal health and have been designated as prebiotics, that 
is non-digestible dietary constituents that benefit host health via selective stimulation of the 
growth and/or activity of certain microorganisms [76]. Prebiotics can originate from a mul-
titude of sources including inulins, unrefined wheat, unrefined barley, raw oats, soybeans 
and non-digestible oligosaccharides such as fructooligosaccharides (FOS), galactooligosac-
charides (GOS), fructans, polydextrose, xylooligosaccharides(XOS) and arabinooligosaccha-
rides (AOS) [77]. A low fibre diet has been associated with a reduced bacterial abundance 
[78] and high consumption of these non-digestible carbohydrates resulted in an increase in 
microbiota gene richness in obese patients [79]. Many studies revealed that a diet rich in 
non-digestible carbohydrates targets the microbiota by increasing probiotic bacteria such 
as bifidobacteria and lactic acid bacteria. Indeed, diets rich in whole grain and wheat bran 
led to an increase of intestinal Bifidobacteria and Lactobacilli [80, 81]. FOS-, polydextrose- 
and AOS-based prebiotics were shown to reduce Clostridium and Enterococcus species. In 
addition, resistant starch and whole grain barley increased the abundance of Ruminococcus, 
E. rectale and Roseburia [61].
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8. The microbiota in type 2 diabetes
Genetics, lifestyle and increased bodyweight all contribute to the development of type 2 dia-
betes. Around 80% of individuals with T2D are overweight thus suggesting an important 
role of diet and microbiota in the pathophysiology of this disease. The link between micro-
biota and T2D first became evident in studies on germ-free mice. Thus, colonization of germ-
free animals with microbiota harvested from conventionally raised mice lead to a significant 
increase in body fat and insulin resistance [82]. A following study showed that germ-free mice 
were resistant to diet-induced obesity [83].
Subsequently, several studies have documented the microbiota shifts associated with 
T2D. After analysing a cohort of Chinese patients with T2D, Qin et al. showed that the 
diabetic microbiome is low in butyrate-producing bacteria such as Clostridiales sp., F. 
prausnitzii, Roseburia intestinalis and E. rectal [84]. Moreover, the T2D intestinal niche con-
tained opportunistic pathogens including the sulfate-reducing Desulfovibrio, Bacteroides 
caccae and E. coli. In line with these findings, a study in Scandinavian post-menopausal 
women revealed decreased levels of F. praunitzii and R. intestinalis in T2D compared 
with individuals having impaired glucose tolerance. In addition, both Chinese and 
Scandinavian T2D cohorts exhibited elevated Lactobacillus levels. Obesity and impaired 
glucose metabolism were reported to have an altered ratio between Bacteroidetes and 
Firmicutes [85]; however, neither the Chinese nor the Scandinavian study found this 
microbiota change.
The Chinese study revealed an increase of E. coli in T2D patients and another Danish study 
showed that Proteobacteria levels were elevated in T2D [86]. These Gram-negative bacte-
ria could potentially be involved in the pathophysiology of T2D. Specifically, the lipopoly-
saccharides (LPS) released by these bacteria could promote a subclinical proinflammation, 
which is typical to both diabetes and obesity. Recent studies revealed that T2D is character-
ized by elevated endotoxemia. Indeed, mice receiving high fat (HF) diet until they developed 
diabetes had endotoxemia, increased intestinal permeability and a distinct microbiots [87]. 
In addition, the term of metabolic infection has emerged in order to describe the role of 
the microbiome in endotoxemia-associated inflammation together with insulin resistance in 
T2D. Endotoxin of microbial origin could play a role in the insulin resistance associated with 
T2D since blood levels of bacterial DNA (mostly Proteobacteria) were shown to be increased 
in prediabetes.
One caveat of the currently available human studies is the lack of information regarding the 
role of antidiabetic medication in altering the microbiota. The first-line drug of choice for type 
2 diabetes treatment is represented by metformin. In the Swedish study, the diabetic patients 
received metformin treatment and their microbiota was enriched in Enterobacteriaceae and 
had low levels of Eubacterium and Clostridium. In mice-fed a high-fat diet, metformin was 
shown to affect both the host glucose metabolism as well as the microbiota by increasing 
the levels of Akkermansia [88]. Recently, metformin treatment has also been shown to alter 
the microbiota composition in T2D patients by increasing Escherichia sp. and decreasing the 
abundance of Intestinibacter sp. (Figure 2) [89].
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9. Probiotic interventions
Due to their anti-inflammatory, hypoglycaemic, insulinotropic, antioxidative and satietogenis 
properties, probiotics can be employed as a treatment for T2D. The insulinotropic effect of genet-
ically engineered Escherichia coli Nissle 1917 for GLP-1 was investigated in Caco-2 cells; it was 
observed that the probiotic strain stimulated the epithelial cells leading to the secretion of insu-
lin corresponding to blood insulin concentration of 164 pmol/ml to 164 nmol/ml [90]. In addi-
tion, Paszti-Gere et al. reported that oxidative stress causing damage to insulin-secreting ß-cells 
was counteracted by metabolites of Lactobacillus plantarum 2142. Specifically, the spent culture 
supernatant of L. plantarum 2142 decreased the oxidative stress-induced overexpression of pro-
inflammatory cytokines IL-8 and TNF-α in IPEC-J2 cell line [91]. The multiple mechanisms of 
probiotics in T2D treatment have emerged from studies by using animal models. Oral adminis-
tration (0.05%) or diet supplementation (0.1%) of heat-killed L. casei in different mouse models 
including KK-Ay mice, NOD mice and Alloxan-induced diabetic mice reduced the plasma glu-
cose level and diabetes development [92, 93]. Feeding neonatal STZ-induced diabetic (n-STZ) 
rats with a diet containing Lactobacillus rhamnosus GG for a period of 9 weeks determined a lower 
blood haemoglobin level and an improved glucose tolerance in comparison to the control group 
Figure 2. The microbiota in type 2 diabetes. Overweight and obese individuals consuming an unhealthy diet such a 
Western diet are prone to develop type 2 diabetes. While healthy individuals consuming a balanced diet with a high 
content of monounsaturated and polyunsaturated fatty acids, elevated vegetable protein content, and high levels of 
antioxidants and fibre harbour a microbiota rich in R. intestinalis, F. prausnitz ii, E. rectale, Lactobacillus sp. and Clostridiales, 
individuals with type 2 diabetes have a microbiota characterized by higher levels of Desulfovibrio sp., Bacteroides sp. and 
Intestinibacter sp.
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receiving a conventional diet. The L. rhamnosus GG treatment group had a serum insulin level 
significantly higher than the control group at 30 min after glucose loading [94]. Furthermore, 
feeding VSL#3 lowered β-cell destruction and inflammation in NOD mice, and this effect was 
accompanied by increased IL-10 secretion in pancreas, Peyer’s patches and spleen. In a sepa-
rate study, the feeding of a probiotic containing Lactobacillus acidophilus NCDC14 and L. casei 
NCDC19 significantly lowered free fatty acids, the blood glucose and glycosylated haemoglo-
bin, and trigycerides in fructose-induced diabetic rats [95]. The feeding of the same probiotic 
to STZ-induced rats suppressed the STZ-induced oxidative damage in pancreatic tissues by 
inhibiting lipid peroxidation, generation of nitric oxide and improved the antioxidant potential 
of glutathione, superoxide dismutase, and catalase and glutathione peroxidase. These data sug-
gest that oral administration of the probiotic significantly ameliorated the risk factors such as 
dyslipidemia, hyperglycemia and oxidative stress in diabetic rats [96]. Probiotic pre-treatment 
with a mixture containing Bifidobacterium lactis, L. acidophilus and L. rhamnosus lowered the 
blood glucose and improved the bioavailability of gliclazide, a second-generation sulphonyl-
urea used for treating non-insulin dependent diabetes mellitus T2D in alloxan induced diabetic 
rats [97]. The antidiabetic effects against insulin resistance of different probiotics can also be due 
to increased liver natural killer T (NKT) cells. NKT cells are involved in regulating the inflam-
matory process in the liver which is the main organ responsible for inflammation-mediated 
insulin resistance. Depletion of liver NKT enhanced the production of pro-inflammatory cyto-
kines, and HFD was known to induce depletion of hepatic NKT cells leading to insulin resis-
tance. HFD-induced depletion of NKT cells in male C57BL-6 mice was significantly improved 
by administration of the VSL#3 probiotic. This probiotic treatment also leads to weight loss, and 
improved insulin resistance and inflammation by modulating TNF-α expression and reducing 
NF-kB binding activity [98]. Treatment with L. plantarum DSM 15313 and L. reuteri GMNL-263 
was reported to lower the blood glucose and glycosylated haemoglobin, in HFD-fed C57BL/6 J 
mice and STZ-induced diabetic rats [99, 100]. DCs from NOD mice were stimulated with three 
different strains of lactobacilli including L. casei, L. reuteri and L. plantarum for a period of 24 h. 
Out of the strains tested, L. casei was found to induce DCs to generate the highest level of IL-10 
and the lowest level of IL-12 expression. When the L. casei-stimulated DCs were transferred to 
NOD mice, they showed a significant delay in diabetes incidence [101]. Bifidobacterium longum 
CGMCC NO. 2107 added as a supplemed in HFD was shown to reduce the metabolic endo-
toxin (LPS) plasma concentrations and to improve intestinal inflammation [102]. Amar et al. 
analysed the effect probiotic treatment has on mucosal dysbiosis, bacterial translocation and 
glucose metabolism [103]. The results obtained revealed that the bacterial translocation was pre-
vented in mice lacking the microbial pattern recognition receptors Nod1 or CD14. Nevertheless, 
it was increased in Myd88 deficient mice and ob/ob mouse under the same conditions. In addi-
tion, the administration of Bifidobacterium animalis subsp. lactis 420 reduced the bacterial trans-
location to mesenteric adipose tissue, decreasing the expression of major pro-inflammatory 
cytokines TNF-a, IL-1b and IL-6 in mesenteric adipose tissue, liver and muscle. In addition, 
 B. animalis subsp. lactis 420 also improved the insulin sensitivity and fasting hyperinsulinaemia 
in HFD fed mice [103].
Since there are a few reports in this area, the knowledge regarding the efficacy of probiotic 
administration in diabetic human subjects is quite limited. Consumption of probiotic yoghurt 
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was shown to improve the antioxidant status and lipid profile in T2D patients. Several ran-
domized, double blind, placebo-controlled clinical trials evaluated the effects of probiotic 
administration on antioxidant status, blood glucose and lipid profile in T2D. The patients with 
T2D mellitus enrolled in these studies were divided into two groups: the probiotic interven-
tion group consumed 300 g/d of probiotic yoghurt containing 106 cfu/mL L. acidophilus La5 and 
106 cfu/mL B. lactis Bb12, whereas the control group consumed 300 g/d of conventional yoghurt 
during a period of 6 weeks. The probiotic treatment cohort exhibited a significant decrease in 
fasting blood glucose as well as an increase in the activities of the erythrocyte superoxide dis-
mutase and glutathione peroxidase. In addition, the total cholesterol: high-density lipoprotein 
(HDL)-C and LDL-C: HDL-C ratios were decreased in the probiotic-treated patients compared 
to the control [104, 105]. Another randomized, double-blind, placebo-controlled study was per-
formed on 20 elderly diabetic volunteers aged 50–60 years, over for a period of 30 days to study 
the effect of a symbiotic drink (a preparation with a combination of both probiotics and pre-
biotics) on glycaemia and cholesterol levels. The symbiotic group that consumed 108 cfu/mL 
Bifidobacterium bifidum, 108 cfu/mL of L. acidophilus, and 2 g oligofructose harboured a signifi-
cantly increased HDL cholesterol, and a decrease in fasting glycemia but, importantly, no sig-
nificant changes were observed in the placebo group [106]. Recently, in a study by Shao et al., 
67 diabetic patients with gastrointestinal cancer were randomized into the probiotic treatment 
group (33 patients receiving enteral nutrition with probiotics, glutamine and fish oil) and the 
control group (34 patients receiving regular enteral nutrition). Fasting blood glucose and insu-
lin were recorded on the day before surgery and post-operative days 3 and 7. Insulin resistance 
index (HOMA-IR) was calculated as well by using the homeostasis model assessment (HOMA) 
for both groups, and the supplementary data on incidence of nosocomial infections, intestinal 
function recovery time and length of hospitalization were also recorded [107].
The enteral nutrition with probiotics, glutathione and fish oil was associated with a low fast-
ing insulin and insulin resistance index compared to the control group. The length of hospital 
stay was significantly decreased from 21 to 17 days in the treatment group. Nevertheless, no 
significant differences in nosocomial infection and intestinal function recovery were observed 
between the two groups. The role of maternal probiotic-supplemented dietary counseling 
during pregnancy on colostrum adiponectin concentration in neonatal nutrition, metabolism 
and immunity was analysed in a randomized, placebo-controlled study by Luoto et al. [108]. 
Specifically, 256 pregnant women were randomized into three groups: dietary intervention 
with probiotics (diet/ L. rhamnosus GG and B. lactis), with placebo (diet/placebo) and a con-
trol cohort (control/placebo). Dietary intake was analysed by food records at each pregnancy 
trimester, and subsequently colostrum samples were collected after birth for the analysis of 
adiponectin concentration. An improved adiponectin concentration is a parameter of neona-
tal metabolic homeostasis and is also an indicator of reduced chances of gestational diabetes. 
Probiotic treatment increased the colostrum adiponectin concentration compared to the con-
trol (12.7 ng/ml vs. 10.2 ng/ml). Nevertheless, other studies state that probiotic use does not 
provide a benefit for the diabetic host. For instance, a randomized, double-blinded clinical 
trial using the commercial probiotic L. acidophilus NCFM in a group of 45 men for a timeframe 
of 4 weeks revealed that there were no changes in the expression of baseline inflammatory 
markers and in the systemic inflammatory response following probiotic treatment [109].
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10. Prebiotics: a useful tool for the management of diabetes
Prebiotics were initially defined as “a non-digestible food ingredient that beneficially affects 
the host by selectively stimulating the growth and/or activity of one or a limited number of 
bacteria in the colon, and thus improves host health” [110]. Later, prebiotics were designated 
as selectively fermented ingredients that allow certain changes in the composition and/or 
activity of the gastrointestinal microbiota that confer benefits upon host well-being and health 
[111]. Prebiotic substances need to meet certain criteria such as: (i) fermentation by the com-
mensal microbiota; (ii) selective stimulation of the growth and/or activity of probiotic bacteria; 
and (iii) resistance to gastric pH, hydrolysis by the host enzymes and gastrointestinal absorp-
tion [112]. The currently known prebiotics which achieve the aforementioned criteria include 
non-digestible carbohydrates, fructooligosaccharides, galactooligosaccharides and lactulose. 
Prebiotics, such as fructooligosaccharides and inulin, undergo digestion by probiotics such 
as bifidobacteria and stimulate their growth [113, 114]. Besides their involvement in stimulat-
ing the expansion of probiotics, prebiotics also stimulate immunity, inhibit pathogen growth 
and produce vitamins. In addition, prebiotics were suggested to promote cell differentiation, 
cell-cycle arrest and apoptosis of transformed colonocytes by epigenetic modifications and by 
decreasing the transformation of bile acids [110]. Prebiotics administration may have a regula-
tory role in modulating endogenous metabolism since the SCFAs obtained as an end product 
of the carbohydrate metabolism improve glucose tolerance. SCFAs also decrease glucagon lev-
els and activate glucagon-like peptide1 (GLP-1), which can stimulate the elevation of insulin 
production and elevate insulin sensitivity [115, 116]. SCFAs were shown to have an important 
role in T2DM patients because they promote secretion of GLP-1, a hormone that inhibits gluca-
gon secretion, decreases hepatic gluconeogenesis and improves insulin sensitivity [117].
Prebiotics were also suggested to lead to hypercholesterolemia by lowering cholesterol absorp-
tion and by the generation of SCFAs upon selective fermentation by commensal microbiota [118]. 
A daily intake of 20 g of the prebiotic inulin significantly lowered serum triglycerides compared 
to the control group. Inulin treatment also decreased serum LDL-cholesterol and increased 
serum HDL-cholesterol [119]. Moreover, normolipidemic individuals consuming 18% of inu-
lin on a daily basis without any other dietary restrictions exhibited a decrease in total plasma 
cholesterol and triacylglycerols as well as an increased fecal concentration of Lactobacillus-
lactate [120]. The inclusion of inulin in the diet of rats increased the excretions of fecal lipids 
and cholesterol compared to that of the control group due to a reduced cholesterol absorption 
[121]. Other prebiotics including resistant starches and their derivatives, oligodextrans, lactose, 
lactoferrin-derived peptides and N-acetylchitooligosaccharides were also shown to have hypo-
cholesterolaemic effects in T2DM patients who are at high risk of developing cardiovascular 
complications [112]. A diet enriched with arabinoxylan and resistant starch consumed by adults 
with metabolic syndrome leads to a reduction in the total species diversity of the faecal associ-
ated intestinal microbiota and an increase in Bifidobacterium and butyrate levels [122].
Clinical trials reported that dietary polyphenols increase the population of Bifidobacterium sp. in 
the gut [123]. Daily consumption of red wine polyphenols for a period of 4 weeks significantly 
increased the levels of Bifidobacterium, Prevotella, Bacteroides, Bacteroides uniformis, Eggerthella 
lenta, Enterococcus, and Blautia coccoides-E. rectale groups compared with baseline, but there 
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was no control drink for comparison [124]. Meta-analyses of acute or short-term, randomized 
controlled trials revealed that chocolate or cocoa-reduced insulin and fasting insulin after glu-
cose challenge and improved insulin resistance with no effect on fasting glucose and glycated 
haemoglobin (HbA1c) [125].
Consumption of dark chocolate containing 500 mg polyphenols for a period of 4 weeks 
reduced blood pressure (BP), fasting glucose and insulin resistance in lean and overweight 
females compared to 20 g of placebo dark chocolate with negligible polyphenol content [126]. 
Drinking cocoa flavanols (902 mg) for 12 weeks also improved insulin sensitivity in over-
weight and obese individuals compared to a low-flavanol cocoa drink [127]. In contrast, daily 
consumption of 25 g dark chocolate for 8 weeks did not ameliorate fasting glucose, insulin 
and HbA1c levels in hypertensive diabetic subjects compared to those consuming 25 g of 
white chocolate [128]. Given the conflicting results obtained, current data are insufficient to 
use cocoa polyphenols for glycaemic control.
Cinnamon contains several polyphenols such as procyanidin, cinnamtannin trans-cinnamic 
acid and flavones (cinnamaldehyde and trans-cinnamaldehyde) and catechin, and several 
studies have shown the positive effects of cinnamon on glycaemic control [123]. Two clinical 
studies reported positive effects of cinnamon on fasting blood glucose levels, but no signifi-
cant changes of HbA1c, LDL, HDL, total cholesterol or TG [129, 130]. Other studies reported 
no significant changes in fasting glucose, lipids, HbA1c, or insulin levels in 43 subjects with 
T2D receiving 1 g of cinnamon daily for 3 months [131], 25 postmenopausal women with T2D 
taking 1.5 g of cinnamon daily for 6 weeks [132], in 11 healthy subjects taking cinnamon (3 g) 
daily for 4 weeks [133], and in 72 adolescents with T1D taking 1 g of cinnamon daily [134]. A 
randomized, placebo-controlled, double-blind clinical trial of 58 subjects with T2D found that 
intake of 2 g daily of cinnamon for 12 weeks significantly reduced HbA1c, systolic blood and 
diastolic blood pressure [135]. Whole grains including wheat, soy, rye and flaxseed and nuts 
such as almonds, pecans and hazelnuts are an important source of polyphenols [136]. Whole 
grain intake is associated with a reduced risk of T2D, but the mechanism of the protection is 
not well understood [137]. Extra virgin olive oil and olive leafs are another source of poly-
phenols such as oleuropein and hydroxytyrosol, and they are suggested to have beneficial 
effects in T2D [138]. The Mediterranean diet supplemented with virgin olive oil or nuts har-
boured anti-inflammatory effects by decreasing chemokines, interleukin-6 (IL-6) and adhe-
sion molecules, and T-lymphocytes and monocytes [139]. A study of 3541 patients with high 
cardiovascular risk revealed that a Mediterranean diet rich in extra virgin oil leads to a 40% 
reduction in the risk of T2D compared with the control group [140].
Supplementation with olive leaf polyphenols improved insulin sensitivity and pancreatic 
β-cells secretory capacity after oral glucose challenge in overweight, middle-aged men at the 
risk of developing metabolic syndrome [141, 142]. Supplementation with a 500 mg olive leaf 
extract tablet for 14 weeks in subjects with T2D significantly lowered HbA1c and fasting insu-
lin but had no effects on postprandial insulin levels [142, 143].
Red wine, berries, grape skins, rhubarb roots, red wine and peanuts, and the roots of rhubarb 
are sources of resveratrol, a polyphenol naturally synthesized by plants in response to infec-
tion and injury. Resveratrol supplementation in obese men for a period of 30 days reduced 
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glucose, insulin, insulin resistance index and leptin, and decreased inflammatory markers 
(TNF-α, leukocytes). Even though resveratrol supplementation also decreased adipose tissue 
lipolysis and plasma fatty acid and glycerol in the postprandial state [144], the study lacked 
some of the necessary controls therefore more investigations are needed in order to state that 
resveratrol has antidiabetic effects.
11. Conclusions and perspectives
The diet-microbiota-diabetes trio is a hot research topic at the moment, and it still requires 
further investigation. Even though several studies highlight the benefits associated to the 
consumption of probiotics in the management of diabetes, their use is hindered by the insuf-
ficient information regarding their mechanisms of action. Furthermore, additional human 
studies are still needed in order to get a better understanding of the role held by the ethnic-
ity and diet in shaping the diabetic microbiome. Finally, future studies combining micro-
biota analysis, metabolomics, proteomics as well as treatment regimens will provide valuable 
information regarding the pathomechanisms of diabetes and potentially ways to prevent the 
onset of disease.
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